Dr Reddy's Laboratories Ltd

The pharmaceutical major has collaborated with MSN Laboratories (MSN), a leading pharmaceutical company in India, on this product. Dr. Reddy's holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product. Bosutinib Tablets was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S. The Bosulif brand had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data. Milan Kalawadia, CEO- North America, Dr. Reddy's Laboratories, Inc. said: This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers. With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company had reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25. The scrip shed 0.09% to end at Rs 1273.90 on the BSE on Friday. Powered by Capital Market - Live

Dr Reddys Laboratories has allotted 12,100 equity shares under ESOS on 05 June 2026. With this allotment, the paid up equity share capital has increased to Rs 83,46,70,070 /-.

Dr. Reddy's Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy's is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on 28 April 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy's readiness to ensure patient access following approval. In Canada, Dr. Reddy's Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection.

Dr Reddys Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 1268.7, down 0.1% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.54% on the day, quoting at 23505.1. The Sensex is at 74897.31, up 0.45%.Dr Reddys Laboratories Ltd has gained around 4.18% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 6.93% in last one month and is currently quoting at 23840.9, up 0.63% on the day. The volume in the stock stood at 77.06 lakh shares today, compared to the daily average of 31.23 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 1269.7, up 0.13% on the day. Dr Reddys Laboratories Ltd jumped 3.99% in last one year as compared to a 4.71% slide in NIFTY and a 11.69% spurt in the Nifty Pharma index.The PE of the stock is 22.85 based on TTM earnings ending December 25.Powered by Capital Market - Live

Securities in F&O Ban: Steel Authority of India are banned from F&O trading on 13 May 2026. Result Today: Balaji Amines, The Bombay Burmah Trading Corporation, Bharti Airtel, Bharti Hexacom, CARE Ratings, Cipla, Crompton Greaves Consumer Electricals, DCM Shriram, DLF, eClerx Services, GlaxoSmithKline Pharmaceuticals, Hindustan Petroleum Corporation, Inventurus Knowledge Solutions, Interarch Building Solutions, JSW Dulux, Kaynes Technology India, Kirloskar Brothers, LIC Housing Finance, Man Infraconstruction, Metropolis Healthcare, NLC India, Oil Indi, Onesource Specialty Pharma, Paras Defence and Space Technologies, Power Finance Corporation, Quality Power Electrical Equipments, Redington, Sagar Cements, Sharda Cropchem, Signatureglobal (India), SKF India, Suven Life Sciences, Tourism Finance Corporation of India, Tube Investments of India, Tata Motors, TVS Holdings, TVS Motor Company, Zaggle Prepaid Ocean Services and ZF Commercial Vehicle Control Systems India Stocks to Watch: Dr. Reddy's Laboratories reported an 86.14% decline in consolidated net profit to Rs 220.9 crore on an 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 compared with Q4 FY25. Berger Paints India reported a 27.9% rise in consolidated net profit to Rs 335 crore from Rs 262 crore. Revenue increased 6.1% to Rs 2,868 crore from Rs 2,704 crore. Dixon Technologies (India) reported a 35.91% decline in consolidated net profit to Rs 297.97 crore on a 2.12% increase in revenue from operations to Rs 10,510.51 crore in Q4 FY26 compared with Q4 FY25. Neuland Laboratories reported a 665.1% jump in consolidated net profit to Rs 212.7 crore from Rs 27.8 crore. Revenue rose 134.8% to Rs 788.7 crore from Rs 335.8 crore. Tata Power reported a 4.5% decline in consolidated net profit to Rs 996 crore from Rs 1,043 crore. Revenue fell 12.9% to Rs 14,900 crore from Rs 17,096 crore. Torrent Power reported a 70% decline in consolidated net profit to Rs 318 crore from Rs 1,059 crore. Revenue slipped 0.8% to Rs 6,406 crore from Rs 6,456 crore. Thomas Cook (India) reported a 40.1% decline in consolidated net profit to Rs 38.7 crore from Rs 64.6 crore. Revenue fell 10.1% to Rs 1,771 crore from Rs 1,969 crore. Kalpataru reported a consolidated net profit of Rs 200 crore compared with Rs 14.1 crore a year ago. Revenue surged 183.7% to Rs 1,694 crore from Rs 597 crore. Powered by Capital Market - Live

Dr Reddys Laboratories has fixed 10 July 2026 as record date for payment of final dividend of Rs 8 per equity share of Re 1 for FY 2025-26.

Net profit of Dr Reddy's Laboratories declined 86.14% to Rs 220.90 crore in the quarter ended March 2026 as against Rs 1593.30 crore during the previous quarter ended March 2025. Sales declined 11.64% to Rs 7516.20 crore in the quarter ended March 2026 as against Rs 8506.00 crore during the previous quarter ended March 2025. For the full year,net profit declined 25.80% to Rs 4196.00 crore in the year ended March 2026 as against Rs 5655.10 crore during the previous year ended March 2025. Sales rose 3.19% to Rs 33593.30 crore in the year ended March 2026 as against Rs 32553.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales7516.208506.00 -12 33593.3032553.50 3 OPM %5.0923.49 -19.2126.26 - PBDT756.802459.90 -69 7451.509383.20 -21 PBT199.702005.20 -90 5392.707679.50 -30 NP220.901593.30 -86 4196.005655.10 -26 Powered by Capital Market - Live

The weak performance was primarily impacted by a sharp decline in North America revenues due to lower sales of Lenalidomide and a one-time shelf stock adjustment (SSA) of Rs 450 crore related to the product. Favourable foreign exchange movements partially offset the decline. Excluding the one-time SSA, consolidated revenues were at Rs 7,970 crore in Q4FY26, a decline of 6.3% YoY and 8.7% QoQ and Rs 34,050 billion in FY26, a growth of 4.6% YoY. Profit before tax (PBT) dropped 90.04% YoY to Rs 199.7 crore in Q4 FY26. EBITDA slipped 60.37% to Rs 980.7 crore in Q4 FY26 compared with Rs 2,474.9 crore in Q4 FY25. EBITDA margin contracted to 13% in Q4 FY26 as against 29.1% in Q4 FY25. Excluding the SSA impact, EBITDA margin stood at 19.5% in Q4 FY26. Revenue from global generics tumbled 13% YoY to Rs 6,580 crore during the quarter. In Q4 FY26, revenue from North America declined 51% YoY to Rs 1,760 crore, Decline was largely due to lower Lenalidomide sales and the one-time SSA. Excluding this one-off, revenues for the segment recorded a 38% YoY decline and a 25% sequential decline in Q4 FY26. Revenue from India jumped 20% YoY to Rs 1,570 crore in Q4 FY26, driven by revenues from new brand launches, including products from its innovation portfolio, price increases, higher volumes and contributions from recently acquired portfolios. Revenue from Europe region increased 14% YoY to Rs 1,450 crore during the quarter, while revenue from emerging markets jumped 29% YoY to Rs 1,810 crore in Q4 FY26, aided by new launches across markets and higher volumes, further supported by favourable forex. R&D Expenses stood at Rs 550 crore during the quarter, registering de-growth of 25% YoY, and accounted for 7.3% of revenue. The decline was mainly due to lower development spending in biosimilars following the completion of major investments related to Abatacept. The company said R&D spending continues to focus on complex generics, peptides and biosimilars. Q4FY26 was also impacted by charges related to certain discontinued CAR-T assets, while FY26 included the one-time new Labour Codes provision. On full year basis, the company's consolidate net profit tumbled 25.8% to Rs 4196 crore despite 3.24% jump in revenue from operations to Rs 33,700.2 crore in FY26 over FY25. Co-Chairman & MD, G V Prasad said: Our performance this year reflects the impact of lower lenalidomide sales and several one-offs. The resilience of our branded businesses and currency tailwinds helped partially mitigate this impact. We remain focused on strengthening our base business and improving margins, through cost efficiencies and portfolio optimization. In parallel, we continue to build long-term franchises in biosimilars, consumer health and innovation to deliver sustainable value.' Meanwhile, the company's board recommended a final dividend of Rs 8 per equity share of face value of Rs 1 each for the financial year 2025-26. The record date for the dividend has been fixed as 10 July 2026. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The scrip shed 0.76% to settle at Rs 1,270.10 on the BSE.Powered by Capital Market - Live

Dr Reddys Laboratories announced that the 42th Annual General Meeting(AGM) of the company will be held on 23 July 2026.

Dr Reddys Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2026, has recommended a Final Dividend of Rs.8 per share (i.e.800%), subject to the approval of the shareholders.